Cytokinetics Reports $28.6 Million Revenue and $198.8 Million Net Loss in Q2 2026

Cytokinetics, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $28.6 million, a significant decrease from $66.8 million in the same period last year. The decline was primarily attributed to a drop in license and milestone revenues, which fell from $64.4 million to zero, while net product revenue from its newly launched drug, MYQORZO® (aficamten), contributed $25.3 million in the quarter. The company also reported collaboration revenues of $3.3 million, up from $2.4 million in the prior year, reflecting ongoing partnerships, particularly with Bayer.

In terms of expenses, Cytokinetics experienced an increase in total operating expenses, which rose to $207.8 million from $178.3 million year-over-year. This increase was driven by higher selling, general, and administrative costs, which surged to $104.4 million from $65.7 million, largely due to expenses related to the commercial launch of MYQORZO. Research and development expenses decreased slightly to $97.8 million from $110.1 million, reflecting a shift in focus as the company transitions to commercialization.

Cytokinetics' net loss for the quarter was $198.8 million, compared to a loss of $134.4 million in the same quarter of 2025. The company’s accumulated deficit has now reached approximately $3.9 billion. As of June 30, 2026, Cytokinetics reported cash, cash equivalents, and investments totaling $1.7 billion, a substantial increase from $1.2 billion at the end of 2025, bolstered by a public offering that raised approximately $760.1 million in May 2026.

Operationally, the company has commenced commercial sales of MYQORZO in the United States and Europe, with initial sales in Germany and China. The drug is aimed at treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and has received regulatory approvals in multiple regions. The company anticipates that MYQORZO will capture a significant market share, potentially exceeding 50% in the U.S. market.

Looking ahead, Cytokinetics expects to continue incurring operating losses as it invests in the commercialization of MYQORZO and the development of its pipeline, which includes ongoing clinical trials for other drug candidates. The company remains focused on generating substantial revenues from MYQORZO and securing additional capital through strategic collaborations and financing to support its operations and growth initiatives.